On Nov 09, major Wall Street analysts update their ratings for $Moderna (MRNA.US)$, with price targets ranging from $60 to $112.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $70.
Goldman Sachs analyst Salveen Richter maintains with a buy rating, and adjusts the target price from $139 to $112.
BofA Securities analyst Alec Stranahan maintains with a hold rating, and adjusts the target price from $110 to $90.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $125 to $111.
Evercore analyst Cory Kasimov maintains with a hold rating, and maintains the target price at $60.
Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:
Moderna's Q3 SpikeVax revenue exceeded expectations and the company maintained its previous guidance. Despite anticipating the approval of two additional vaccines, the company presented a prudent projection for the year 2025.
Moderna's recent quarterly performance surpassed expectations, mainly due to an earlier commencement of the vaccination season compared to the previous year. Nonetheless, the company has moderated its vaccination rate outlook for the year, shifting from 'flat' in comparison to last year to a potential decline of up to 10%. Additionally, while revenue guidance for the year remains unchanged, expectations have been adjusted to conclude towards the lower end of the projected range.
Here are the latest investment ratings and price targets for $Moderna (MRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
